Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-06-14
2011-06-14
Zara, Jane (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S184100, C424S278100, C514S001100, C536S023100
Reexamination Certificate
active
07960362
ABSTRACT:
The invention relates to synthetic chemical compositions that are useful for modulation of Toll-Like Receptor (TLR)-mediated immune responses. In particular, the invention relates to agonists of Toll-Like Receptor 9 (TLR9) that generate unique cytokine and chemokine profiles.
REFERENCES:
patent: 6503734 (2003-01-01), Craft et al.
patent: 6790640 (2004-09-01), Craft et al.
patent: 7276489 (2007-10-01), Agrawal et al.
patent: 2006/0058254 (2006-03-01), Dina et al.
patent: 2008/0292648 (2008-11-01), Kandimalla et al.
patent: 2008/0311112 (2008-12-01), Hackam et al.
patent: 2009/0317480 (2009-12-01), Fearon et al.
patent: WO 02/052002 (2002-07-01), None
patent: WO 2004/058179 (2004-07-01), None
Zhao et al.; “Effect of Different Chemically Modified Oligodeoxynucleotides on Immune Stimulation”; Biochem. Pharmacol. 1996, 26:173-182.
Hemmi et al.; “A Toll-like receptor recognizes bacterial DNA”; Nature 2000, 408:740-745.
Zhao et al.; “Modulation of Oligonucleotide-Induced Immune Stimulation by Cyclodextrin Analogs”; Biochem Pharmacol. 1996, 52:1537-1544.
Zhao et al.; “Pattern and Kinetics of Cytokine Production Following Administration of Phosphorothioate Oligonucleotides in Mice”; Antisense Nucleic Acid Drug Dev. 1997, 7:495-502.
Zhao et al.; “Site of Chemical Modifications on CpG Containing Phosphorothioate Oligodeoxynucleotide Modulates its Immunostimulatory Activity”; Bioorg. Med. Chem. Lett. 1999, 9:3453-3458.
Zhao et al.; “Immunostimulatory Activity of CpG Containing Phosphorothioate Oligodeoxynucleotide is Modulated by Modification of a Single Deoxynucleoside”; Bioorg. Med. Chem. Lett. 2000, 10:1051-1054.
Yu et al.; “Accessible 5′-End of CpG-Containing Phosphorothioate Oligodeoxynucleotides is Essential for Immunostimulatory Activity”; Bioorg. Med. Chem. Lett. 2000, 10:2585-2588.
Yu et al.; “Modulation of Immunostimulatory Activity of CpG Oligonucleotides by Site-Specific Deletion of Nucleobases”; Bioorg. Med. Chem. Lett. 2001, 11:2263-2267.
Kandimalla et al.; “Effect of Chemical Modifications of Cytosine and Guanine in a CpG-Motif of Oligonucleotides: Structure-Immunostimulatory Activity Relationships”; Bioorg. Med. Chem. 2001, 9:807-813.
Kandimalla et al.; “Immunomodulatory Oligonucleotides Containing a Cytosine-Phosphate-2′-deoxy-7-deazaguanosine Motif as Potent Toll-Like Receptor 9 Agonists”; Proc Natl. Acad. Sci. USA, 2005, 102:6925-6930.
Kandimalla et al.; “A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif”; Proc Natl Acad. Sci USA, 2003, 100:14303-14308.
Cong et al.; “Self-stabilized CpG DNAs optimally activate human B cells and plasmacytoid dendritic cells”; Biochem Biophys Res Commun. 2003, 310:1133-1139.
Kandimalla et al.; “Secondary Structures in CpG Oligonucleotides Affect Immunostimulatory Activity”; Biochem Biophys Res Commun. 2003, 306:948-953.
Kandimalla et al.; “Divergent Synthetic Nucloetide Motif Recognition Pattern: Design and Development of Potent Immunomodulatory Oligodeoxyribonucleotide Agents with Distinct Cytokine Induction Profiles”; Nucleic Acids Res. 2003, 31:2393-2400.
Yu et al.; “Requirement of Nucleobase Proximal to CpG Dinucleotide for Immunostimulatory Activity of Synthetic CpG DNA”; Bioorg. Med. Chem. 2003, 11:459-464.
Bhagat et al.; “CpG Penta- and Hexadeoxyribonucleotides as Potent Immunomodulatory Agents”; Biochem Biophys Res Commun. 2003, 300:853-861.
Yu et al.; “Immunomers'-Novel 3′-3′-Linked CpG Oligodeoxyribonucleotides as Potent Immunomodulatory Agents”; Nucleic Acids Res. 2002, 30:4460-4469.
Yu et al.; “Design, Synthesis, and Immunostimulatory Properties of CpG DNAs Containing Alkyl-Linker Substitutions: Role of Nucleosides in the Flanking Sequences”; J. Med. Chem. 2002, 45:4540-4548.
Yu et al.; “Potent CpG Oligonucleotides Containing Phosphodiester Linkages: In Vitro and In Vivo Immunostimulatory Properties”; Biochem Biophys Res. Commun. 2002, 297:83-90.
Kandimalla et al.; “Conjugation of Ligand at the 5′-End of CpG DNA Affects Immunostimulatory Activity”; Bioconjug. Chem. 2002, 13:966-974.
Yu et al.; “Immunostimulatory Properties of Phosphorothioate CpG DNA Containing Both 3′-5′-and 2′-5-Internucleotide Linkages”; Nucleic Acids Res. 2002, 30:1613-1619.
Yu et al.; “Immunostimulatory Activity of CpG Oligonucleotides Containing Non-Ionic Methylphosphonate Linkages”; Bioorg. Med. Chem. 2001, 9:2803-2808.
Putta et al.; “Novel Oligodeoxynucleotide Agonists of TLR9 Containing N3-Me-dC or N1-Me-dG Modifications”; Nucleic Acids Res. 2006, 34:3231-3238.
Hornung et al.; “Quantitative Expression of Toll-Like Receptor 1-10 mRNA in Cellular Subsets of Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides”; J. Immunol., 2002, 168:4531-4537.
Poltorak et al.; “Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene”; Science, 1998, 282:2085-2088.
Underhill et al.; “The Toll-Like Receptor 2 is Recruited to Macrophage Phagosomes and Discriminates Between Pathogens”; Nature, 1999, 401:811-815.
Hayashi et al.; “The Innate Immune Response to Bacterial Flagellin Is Mediated by Toll-Like Receptor 5”; Nature, 2001, 410:1099-1103.
Zhang et al.; “A Toll-like Receptor That Prevents Infection by Uropathogenic Bacteria”; Science, 2004, 303:1522-1526.
Meier et al.; “Toll-Like Receptor (TLR) 2 and TLR4 Are Essential for Aspergillus-Induced Activation of Murine Macrophages”; Cell. Microbiol. 2003, 5:561-570.
Campos et al.; “Activation of Toll-Like Receptor-2 by Glycosylphosphatidylinositol Anchors from a Protozoan Parasite1”; J. Immunol, 2001, 167:416-423.
Hoebe et al.; “Identification of Lps2 as a Key Transducer of MyD88-Independent TIR Signalling”; Nature, 2003, 424:743-748.
Lund et al.; “Toll-like Receptor 9—mediated Recognition of Herpes Simplex Virus-2 by Plasmacytoid Dendritic Cells”; J. Exp. Med., 2003, 198:513-520.
Heil et al.; “Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8”; Science, 2004, 303:1526-1529.
Diebold et al.; “Innate Antiviral Responses by Means of TLR7-Mediated Recognition of Single-Stranded RNA”; Science, 2004, 303:1529-1531.
Hornung et al.; “Replication-Dependent Potent IFN-alpha Induction in Human Plasmacytoid Dendritic Cells by a Single-Stranded RNA Virus1”; J. Immunol., 2004, 173:5935-5943.
Akira et al.; “Toll-Like Receptors: Critical Proteins Linking Innate and Acquired Immunity”; Nature Immunol., 2001, 2:675-680.
Medzhitov; “Toll-Like Receptors and Innate Immunity”; Nature Rev. Immunol., 2001, 1:135-145.
Smith and Wickstrom; “Antisense c-myc and Immunostimulatory Oligonucleotide Inhibition of Tumorigenesis in a Murine B-Cell Lymphoma Transplant Model”; J. Natl. Cancer Inst., 1998, 90:1146-1154.
Vincenzo et al; “Novel Toll-Like Receptor 9 Agonist Induces Epidermal Growth Factor Receptor (EGFR) Inhibition and Synergistic Antitumor Activity with EGFR Inhibitors”; Clin. Cancer Res., 2006, 12(2):577-583.
Agrawal Sudhir
Bhagat Lakshmi
Kandimalla Ekambar
Putta Mallikarjuna
Wang Daqing
Idera Pharmaceuticals Inc.
McDonnell Boehnen & Hulbert & Berghoff LLP
Zara Jane
LandOfFree
Synthetic agonists of TLR9 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synthetic agonists of TLR9, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthetic agonists of TLR9 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2658324